Abstract

Purpose: This study aims to evaluate the effectiveness of BTX-A therapy in the management of AACE in pediatric and young adult populations, shedding light on the evolving landscape of AACE in the digital age. Study design: A retrospective analysis of 27 patients presenting with AACE between January 2020 and June 2023 was conducted. Patients underwent BTX-A therapy, and outcomes were assessed based on ocular alignment, binocular single vision, sensory fusion, and recurrence rates. Results: The study revealed that BTX-A therapy led to a statistically significant reduction in the angle of deviation. Over half of the patients achieved optimal outcomes, with improvements in stereopsis and sensory fusion. Early intervention (within 3 months of symptom onset) significantly correlated with treatment success. Conclusion: This study highlights the evolving nature of AACE in the digital age and underscores BTX-A therapy's role as a globally recognized treatment modality with favorable outcomes.

Full Text